Is there an association between SV40 contaminated polio vaccine and lymphoproliferative disorders? An age-period-cohort analysis on Norwegian data from 1953 to 1997

International Journal of Cancer

Volumn 118, Issue 8, 2006, Pages 2035-2039

  Thu, Guri Olsen ^a   Hem, Ling Yuan ^a   Hansen, Svein ^a   Møller, Bjørn ^a   Norstein, Jarle ^a   Nøkleby, Hanne ^b   Grotmol, Tom ^a  

^a CANCER REGISTRY OF NORWAY   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Lymphocytic leukemia; Non Hodgkin's lymphoma; Polio vaccine; SV40

Indexed keywords

POLIOMYELITIS VACCINE;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CONTAMINATION; FEMALE; GROUPS BY AGE; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; NORWAY; PLASMA CELL LEUKEMIA; POLIOMYELITIS; PRIORITY JOURNAL; SEX RATIO; SIMIAN VIRUS 40; VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DRUG CONTAMINATION; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NORWAY; POLIOVIRUS VACCINES; RISK FACTORS; SIMIAN VIRUS 40;

EID: 33645213898     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21603     Document Type: Article

References (51)

1. Liu S, Semenciw R, Mao Y. Increasing incidence of non-Hodgkin lymphoma in Canada, 1970-1996: age-period-cohort analysis. Hematol Oncol 2003;21:57-66.
2. Clarke CA, Glaser SL. Changing coincidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015-23.
3. Pollán M, López-Abente G, Moreno C, Vergara A, Aragonés N, Ruiz M, Ardanaz E, Moreo P. Rising incidence of Non-Hodgkin lymphoma in Spain: analysis of period of diagnosis and cohort effects. Cancer Epidemiol Biomarkers Prev 1998;7:621-5.
4. Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet 2003;362:139-46.
5. Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, de Sanjose S, Tumino R, Vornanen M. The rise in incidence of lymphomas in Europe 1985-1992. Eur J Cancer 1999;35:627-33.
6. Munksgaard L, Hjalgrim H, Melbye M. [Infectious causes of non-Hodgkin lymphomas]. Ugeskr Laeger 2002;164:5927-32. Danish.
7. Cancer Registry of Norway, Oslo, Norway 2005. Cancer in Norway 2002.
8. Sweet BH, Hilleman MR. The vacuolating virus, SV40. Proc Soc Exp Biol Med 1960;105:420-7.
9. Butel JS, Lednicky JA. Cell and molecular biology of simian virus 40: implications for human infections and disease. J Natl Cancer Inst 1999;91:119-34.
10. www.fhi.no/vaksine/barnevaksinasionsprogrammet
11. Orstavik I, Flugsrud L. [Immunity to poliomyelitis. Study of a group of mothers and their newborn babies at delivery]. Tidsskr Nor Laegeforen 1966;86(3):164-6. Norwegian.
12. Diamandopoulos GT. Leukemia, lymphoma, and osteosarcoma induced in the Syrian golden hamster by simian virus 40. Science 1972;176:173-5.
13. Nakatsuka S, Liu A, Dong Z, Nomura S, Takakuwa T, Miyazato H, Aozasa K, Osaka Lymphoma Study Group. Simian virus 40 sequences in malignant lymphomas in Japan. Cancer Res 2003;63:7606-8.
14. Vilchez RA, Madden CR, Kozinetz CA, Halvorson SJ, White ZS, Jorgensen JL, Finch CJ, Butel JS. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002;359:817-23.
15. Shivapurkar N, Harada K, Reddy J, Scheuermann RH, Xu Y, McKenna RW, Milchgrub S, Kroft SH, Feng Z, Gazdar AF. Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 2002;359:851-2.
16. David H, Mendoza S, Konishi T, Miller CW. Simian virus 40 is present in human lymphomas and normal blood. Cancer Lett 2001;162:57-64.
17. Yazdi AS, Puchta U, Flaig MJ, Sander CA. Lack of evidence for the presence of simian virus 40 DNA in cutaneous lymphomas. J Invest Dermatol 2003;121:212-3.
18. MacKenzie J, Wilson KS, Perry J, Gallagher A, Jarrett RF. Association between simian virus 40 DNA and lymphoma in the United Kingdom. J Natl Cancer Inst 2003;95:1001-3.
19. Rizzo P, Carbone M, Fisher SG, Matker C, Swinnen LJ, Powers A, Di Resta I, Alkan S, Pass HI, Fisher RI. Simian virus 40 is present in most United States human mesotheliomas, but it is rarely present in non-Hodgkin lymphoma. Chest 1999;116:4708-4735.
20. Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003;95:1522-30.
21. De Sanjose S, Shah KV, Domingo-Domenech E, Engels EA, de Sevilla A, Alvaro T, Garcia-Villanueva M, Romagosa V, Gonzalez-Barca E, Viscidi RP. Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer 2003;104:522-4.
22. Engels EA, Katki HA, Nielsen NM, Winther JF, Hjalgrim J, Gjerris F, Rosenberg PS, Frisch M. Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40. J Natl Cancer Inst 2003;95:532-9.
23. Innis MD. Oncogenesis and poliomyelitis vaccine. Nature 1968;219:972-3.
24. Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 1973;2:229-35.
25. Farwell JR, Dohrmann GJ, Marrett LD, Meigs JW. Effect of SV40 virus-contaminated polio vaccine on the incidence and type of CNS neoplasms in children: a population-based study. Trans Am Neurol Assoc 1979;104:261-4.
26. Geissler E. SV40 and human brain tumors. Prog Med Virol 1990;37:211-22.
27. Fraumeni JF, Ederer F, Miller RW. An evaluation of the carcinogenicity of simian virus 40 in man. JAMA 1963;185:713-8.
28. Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 1998;94:227-33.
29. Strickler HD, Rosenberg PS, Devesa SS, Hertel J, Fraumeni JF, Goedert JJ. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998;279:292-5.
30. Carroll-Pankhurst C, Engels EA, Strickler HD, Goedert JJ, Wagner J, Mortimer EA. Thirty-five year mortality following receipt of SV40-contaminated polio vaccine during the neonatal period. Br J Cancer 2001;85:1295-7.
31. Rollison DE, Page WF, Crawford H, Gridley G, Wacholder S, Martin J, Miller R, Engels EA. Case-control study of cancer among US Army veterans exposed to simian virus 40-contaminated adenovirus vaccine. Am J Epidemiol 2004;160:317-24.
32. Engels EA, Chen J, Viscidi RP, Shah KV, Daniel RW, Chatterjee N, Klebanoff MA. Poliovirus vaccination during pregnancy, maternal seroconversion to simian virus 40, and risk of childhood cancer. Am J Epidemiol 2004;160:306-16.
33. Fisher SG, Weber L, Carbone M. Cancer risk associated with simian virus 40 contaminated polio vaccine. Anticancer Res 1999;19:2173-80.
34. Strickler HD, Goedert JJ, Devesa SS, Lahey J, Fraumeni JF, Jr, Rosenberg PS. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst 2003;95(1):38-45.
35. Harvei S, Tretli S, Langmark F. Quality of prostate cancer data in the cancer registry of Norway. Eur J Cancer 1996;32A:104-10.
36. Lund E, Lie SO. Incidence of acute leukaemia in Norway 1957-1981. Scand J Haematol 1983;31:488-94.
37. Clayton D, Schifflers E. Models for temporal variation in cancer rates. II: Age-period-cohort models. Stat Med 1987;6:469-81.
38. McCullagh P, Nelder JA. Generalized linear models. London: Chapman & Hall, 1989.
39. Moller B, Weedon-Fekjaer H, Hakulinen T, Tryggvadóttir L, Storm HH, Talbäck M, Haldorsen T. The influence of mammographic screening on national trends in breast cancer incidence. Eur J Cancer Prev 2005;14:117-28.
40. Girardi AJ, Sweet BH, Hilleman MR. Factors influencing tumor induction in hamsters by vacuolating virus, SV40. Proc Soc Exp Biol Med 1963;112:662-7.
41. World Health Organization Classification of Tumours. Tumours of Haemotopoietic and Lymphoid Tissues. 2001:12-13.
42. Gogstad AC, Vagsholm AB. [Health status during the occupation years-morbidity]. Tidsskr Nor Laegeforen 1990;110:2184-7. Norwegian.
43. Gogstad AC. [Health status during the occupation years-mortality]. Tidsskr Nor Laegeforen 1990;110:2188-92. Norwegian.
44. Kinlen LJ, O'Brien F, Clarke K, Balkwill A, Matthews F. Rural population mixing and childhood leukaemia: effects of the North Sea oil industry in Scotland, including the area near Dounreay nuclear site. BMJ 1993;306:743-8.
45. Kinlen LJ, Dickson M, Stiller CA. Childhood leukaemia and non-Hodgkin lymphoma near large rural construction sites, with a comparison with Sellafield nuclear site. BMJ 1995;310:763-8.
46. Kinlen LJ, Balkwill A. Infective cause of childhood leukaemia and wartime population mixing in Orkney and Shetland, UK. Lancet 2001;357:858.
47. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin lymphoma. Oncogene 2004;23:6524-34.
48. zur Hausen H. Editorial. Int J Cancer 2003;107:687.
49. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 2004;364:1157-66.
50. Vilchez RA, Kozinetz CA, Butel JS. Conventional epidemiology and the link between SV40 and human cancers. Lancet Oncol 2003;4:188-91.
51. Shah KV, Galloway DA, Knowles WA, Viscidi RP. Simian virus 40 (SV40) and human cancer: a review of the serological data. Rev Med Virol 2004;14:231-9.